Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare the effectiveness of usual treatments for lymphedema (massage and elastic sleeve), instituted even before the development of swelling, compared to the use of a newly marketed device, the Flexitouch®, which electronically simulates the effect of massage upon lymph flow.
| Condition | Intervention |
|---|---|
|
Lymphedema Breast Cancer |
Device: Flexitouch |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) Primary Purpose: Prevention |
| Official Title: | To Prospectively Evaluate the Potential for Simple, Effective Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status |
- New development of lymphedema by bioimpedance spectroscopy [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- To prospectively assess the presence of newly developing lymphedema in each study subgroup through serial assessment of segmental interstitial fluid content by multiple frequency bioimpedance [ Time Frame: 3 years of semi-annual follow-up ] [ Designated as safety issue: No ]
- new increases in limb volume [ Time Frame: 36 months ] [ Designated as safety issue: No ]
- To evaluate the preventive interventions in a prospective, randomized fashion, contrasting the responses of equivalent numbers of patients randomized to 2 experimental arms and the control arm of the study [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- To correlate the bioimpedance findings with concurrently derived, serial assessments of limb volume [ Time Frame: 3 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 200 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | May 2015 |
| Estimated Primary Completion Date: | May 2015 (Final data collection date for primary outcome measure) |
-
Device: Flexitouch
- Tactile Systems Technology, Inc.
- biocompression
The current investigation is designed to prospectively evaluate the potential for simple, effective lymphedema prophylaxis in breast cancer survivors who show early evidence of high-risk status. There is growing evidence that the mechanisms of lymphatic repair after injury are mediated through lymphatic flow. Accordingly, we propose that physical measures designed to prophylactically augment lymphatic flow after surgical interventions for breast cancer will reduce the incidence and degree of lymphatic stagnation when compared to patients who receive conventional 'watch and wait' interventions.
The specific aims of the study are
- to prospectively assess the presence of newly developing lymphedema in each study subgroup through serial assessment of segmental interstitial fluid content by multiple frequency bioimpedance
- to evaluate the preventive interventions in a prospective, randomized fashion, contrasting the responses of equivalent numbers of patients randomized to 2 experimental arms and the control arm of the study
- to correlate the bioimpedance findings with concurrently derived, serial assessments of limb volume
Recent advances in our comprehension of the biological processes of lymphatic development and repair suggest that these mechanisms may be able to be manipulated to enhance the regenerative responses in the lymphatic vasculature following injury. Breast cancer-associated lymphedema is a prototype of such an acquired form of lymphatic vasculature insufficiency. Clinically, this poses a substantial clinical problem. It is estimated at one woman in four who survives a breast cancer intervention will develop lymphedema, often progressively. The appearance of lymphedema has documented adverse effects on physical and psychologically well-being. Our new insights into lymphatic repair suggest that such mechanisms can be employed in a prophylactic fashion to forestall or eliminate the development of lymphedema. This proposal is designed to investigate this hypothesis in a prospective fashion, using a randomized trial design in 80 patients enrolled at the time of breast cancer surgery. If the investigation documents a beneficial effect of preventive measures, it could have a profound impact on subsequent breast cancer care. These measures are simple and cost-effective and, could help to eliminate the impact of a substantial detractor to the improved longevity and health that breast cancer survivors otherwise may expect to enjoy.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients referred to the surgeons of the Stanford University Breast Cancer Program
- Patients will be required to have the capacity to provide informed consent.
- All experimental protocols will be reviewed and approved by the Stanford Institutional Review Board for the Protection of Human Subjects.
- All of the subjects to be enrolled in the proposed studies will be patients with unilateral breast cancer who are scheduled to undergo breast surgery and axillary lymph node dissection, with or without breast conserving techniques.
Exclusion Criteria:
- Patients with other serious systemic illness (renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would confound the study or impair the patients' ability to participate.
- Patients with recurrent breast cancer or other forms of pre-existing lymphedema will be ineligible.
Contacts and Locations| Contact: Les Roche, RN | (650) 724-5913 | lesroche@stanford.edu |
| United States, California | |
| Stanford University School of Medicine | Recruiting |
| Stanford, California, United States, 94305 | |
| Contact: Les Roche, RN 650-724-5913 lesroche@stanford.edu | |
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |
| Principal Investigator: Stanley G Rockson | |
| Principal Investigator: | Stanley G Rockson | Stanford University |
More Information
No publications provided
| Responsible Party: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00383500 History of Changes |
| Other Study ID Numbers: | BRSNSTU0007, 95970 |
| Study First Received: | September 29, 2006 |
| Last Updated: | October 25, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Breast Neoplasms Lymphedema Neoplasms by Site Neoplasms |
Breast Diseases Skin Diseases Lymphatic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013